WO2010094981A3 - Thérapie par anticorps - Google Patents

Thérapie par anticorps Download PDF

Info

Publication number
WO2010094981A3
WO2010094981A3 PCT/GB2010/050304 GB2010050304W WO2010094981A3 WO 2010094981 A3 WO2010094981 A3 WO 2010094981A3 GB 2010050304 W GB2010050304 W GB 2010050304W WO 2010094981 A3 WO2010094981 A3 WO 2010094981A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibody therapy
cathepsin
antibody molecule
antibodies
Prior art date
Application number
PCT/GB2010/050304
Other languages
English (en)
Other versions
WO2010094981A2 (fr
Inventor
Shane Olwill
Richard Buick
Hang Fai Kwok
James Johnston
Christopher Scott
Claire Ward
Original Assignee
Fusion Antibodies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Antibodies Limited filed Critical Fusion Antibodies Limited
Publication of WO2010094981A2 publication Critical patent/WO2010094981A2/fr
Publication of WO2010094981A3 publication Critical patent/WO2010094981A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes d'inhibition de l'angiogénèse, consistant à : administrer simultanément, séquentiellement ou de manière séparée (i) une molécule d'anticorps anti-cathepsine S, et (ii) une molécule d'anticorps anti-VEGF. L'invention concerne également des anticorps humanisés anti-cathepsine S, des compositions pharmaceutiques et des méthodes de traitement utilisant lesdits anticorps.
PCT/GB2010/050304 2009-02-20 2010-02-22 Thérapie par anticorps WO2010094981A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0902916.6 2009-02-20
GBGB0902916.6A GB0902916D0 (en) 2009-02-20 2009-02-20 Antibody therapy

Publications (2)

Publication Number Publication Date
WO2010094981A2 WO2010094981A2 (fr) 2010-08-26
WO2010094981A3 true WO2010094981A3 (fr) 2010-12-23

Family

ID=40565474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050304 WO2010094981A2 (fr) 2009-02-20 2010-02-22 Thérapie par anticorps

Country Status (2)

Country Link
GB (1) GB0902916D0 (fr)
WO (1) WO2010094981A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063395A1 (fr) * 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Anticorps humanisés dirigés contre inkt
CN114989297B (zh) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 包含辣根过氧化物酶标记的抗体的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109045A2 (fr) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Anticorps et leurs utilisations
WO2008044076A2 (fr) * 2006-10-12 2008-04-17 Fusion Antibodies Limited Anticorps et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
CA2134773A1 (fr) 1992-06-04 1993-12-09 Robert J. Debs Methodes et compositions pour genotherapie in vivo
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109045A2 (fr) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Anticorps et leurs utilisations
WO2008044076A2 (fr) * 2006-10-12 2008-04-17 Fusion Antibodies Limited Anticorps et leurs utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURDEN ROBERTA E ET AL: "Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis", CLINICAL CANCER RESEARCH, vol. 15, no. 19, October 2009 (2009-10-01), pages 6042 - 6051, XP002583183, ISSN: 1078-0432 *
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB LNKD- DOI:10.1006/JMBI.1996.0548, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.79.6.1979, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *
TOL JOLIEN ET AL: "Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US LNKD- DOI:10.1056/NEJMOA0808268, vol. 360, no. 6, 1 February 2009 (2009-02-01), pages 563 - 572, XP002526064, ISSN: 0028-4793 *
VAJDOS F F ET AL: "Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB LNKD- DOI:10.1016/S0022-2836(02)00264-4, vol. 320, no. 2, 5 July 2002 (2002-07-05), pages 415 - 428, XP004449739, ISSN: 0022-2836 *
WU HERREN ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY,, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP002582261 *

Also Published As

Publication number Publication date
GB0902916D0 (en) 2009-04-08
WO2010094981A2 (fr) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2007115049A3 (fr) Anticorps monoclonaux humanisés contre le facteur de croissance des hépatocytes
WO2011143624A3 (fr) Anticorps monoclonaux anti-cd47 humanisés et chimères
WO2011003557A8 (fr) Complexe d'anticorps bispécifique et de digoxigénine conjugué à un agent thérapeutique ou de diagnostic
WO2013072813A3 (fr) Peptides cytotoxiques et conjugués anticorps-médicaments de ceux-ci
WO2011110642A3 (fr) Anticorps monoclonaux contre c-met
EP3539988A3 (fr) Anticorps monoclonaux contre her2
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
WO2010066803A3 (fr) Anticorps humains du facteur tissulaire
WO2011160119A3 (fr) Anticorps contre gd2
WO2010054265A3 (fr) Anticorps monoclonaux anti-récepteur 2 du facteur de croissance des fibroblastes
WO2012149356A3 (fr) Anticorps anti-cd40 et leurs procédés d'utilisation
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2012064792A3 (fr) Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2008121615A3 (fr) Formulation d'anticorps
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
WO2009112245A9 (fr) Anticorps contre le csf-1r
WO2014031487A8 (fr) Inhibiteurs bivalents de protéines iap et méthodes thérapeutiques les utilisant
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10706043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10706043

Country of ref document: EP

Kind code of ref document: A2